# CALM (NCT02746952)

> Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

No report yet. It can be ordered.

- Drugs tested: UCART19
- Indication: relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02746952
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Institut de Recherches Internationales Servier
- Conditions: B-cell Acute Lymphoblastic Leukemia
- Interventions: UCART19
- Enrollment: 25
- Primary outcome: Dose escalation part: Dose Limiting Toxicities (DLTs) occurence. Dose expansion part: AE throughout the study.

## Indexed commentary on CALM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- Podcasts: 3
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=calm-nct02746952

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02746952", "email": "<work email>"}; the inbox owner confirms by the emailed link.